CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: https://lnkd.in/eSmpkEZN
CDR-Life Inc.’s Post
More Relevant Posts
-
Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc https://lnkd.in/ecqjqda3
To view or add a comment, sign in
-
New 3i Investigator Article Alert!! First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors https://lnkd.in/daUuU4Bs
To view or add a comment, sign in
-
#KeiretsuBacked Seneca Therapeutics, Inc. achieves another milestone with the publication of the TEM8 review article “TEM8 in Oncogenesis" in the Cells Journal. Read more about how it sheds light on TEM8's pivotal role in solid tumors: https://bit.ly/4agnbyy #SenecaTherapeutics #TEM8Research #OncogenesisInsights #CellsJournal #CancerResearch
To view or add a comment, sign in
-
Join our webinar on January 17th at noon to learn how Lisata Therapeutics is focusing on ways to target and penetrate solid tumors. https://hubs.la/Q02fwY5d0
To view or add a comment, sign in
-
Learn about NEXUS-01, our Phase 1 trial of an investigational #Nectin4 targeted antibody-drug conjugate in patients with advanced or metastatic #UrothelialCarcinoma or other solid tumors. Find detailed trial and enrollment information here: https://e.lilly/3VR2ns8 #CancerResearch #ClinicalTrials #ADCs #BladderCancer
To view or add a comment, sign in
-
#KeiretsuBacked Seneca Therapeutics, Inc. achieves another milestone with the publication of the TEM8 review article “TEM8 in Oncogenesis" in the Cells Journal. Read more about how it sheds light on TEM8's pivotal role in solid tumors: https://bit.ly/4agnbyy #SenecaTherapeutics #TEM8Research #OncogenesisInsights #CellsJournal #CancerResearch
To view or add a comment, sign in
-
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
To view or add a comment, sign in
-
🎙 Tune in to OncologyTube.com to hear our Vice President of Clinical Development, Kellogg Parsons, MD, MHS, FACS at #SABC23, overview the applications of our lead investigational #ADC therapeutic, MBRC- 101, which targets EphA5 in advanced #solidtumors and shows promise in various cancers, including #breastcancer subtypes. Listen here: https://lnkd.in/gckw7gqW
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors - SABCS 2023
oncologytube.com
To view or add a comment, sign in
-
With the advancement of two clinical trials treating KRAS G12D mutated cancers and the initiation of GLP toxicology studies for QTX3544, a G12V-preferring multi-#KRAS inhibitor, we aim to address the significant unmet need for patients with KRAS-mutated cancer beyond G12C.
Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0
To view or add a comment, sign in
-
Context acquired CT-95, a potentially first-in-class mesothelin (“MSLN”) x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. Learn more here. https://lnkd.in/gVu_g6zw
To view or add a comment, sign in
3,810 followers